Autres langues Fortress Biotech, Inc.

Actions

FBIO

US34960Q3074

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
1,8 ^USD	+3,45%		+4,65%	-40,20%

28/03	Fortress Biotech, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
19/03	FORTRESS BIOTECH, INC. : Alliance Global Partners toujours positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	01/05
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	29/04
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	25/04
Avenue Therapeutics Announces Reverse Stock Split	24/04
North American Morning Briefing : Powell Awaited -2-	03/04
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02/04
Certain Options of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02/04
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02/04
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	28/03
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26/03
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	21/03
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18/03
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	15/03
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	13/03
Fortress Biotech to Participate in 36th Annual ROTH Conference	12/03
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	11/03
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease	04/03
Certain Preferred Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	08/02
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	08/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Fortress Biotech, Inc.

Actions

FBIO

US34960Q3074

Autres langues

Filtres